General Information
DRAVP ID DRAVPe00791
Peptide Name LP-95
Sequence IEELLKKAEEQQKKNEEELKX
Sequence Length 21
UniProt ID P03377
Source Synthetic construct
Activity Information
Target Organism HIV,SIV
Assay cell-fusion assay,single-cycle infection assay
Activity
Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry
Cytotoxicity
Binding Target membrane
Mechanism The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities.
Structure Information
PDB ID None
Predicted Structure Download No predicted structure available
Linear/Cyclic Linear
N-terminal Modification Acetylation
C-terminal Modification Amidation
Other Modification The 'X' at position 21 is Lys-Chol(cholesterol)
Stereochemistry L
Physicochemical Information
Formula C106H180N28O37
Absent amino acids CDFGHMPRSTVWY
Common amino acids E
Mass 2568.11
Pl 4.86
Basic residues 5
Acidic residues 7
Hydrophobic residues 5
Net charge -2
Boman Index -7165
Hydrophobicity -175.24
Aliphatic Index 79.05
Half Life
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 1
Literature Information
Literature 1
Title Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
Pubmed ID 30867304
Reference J Virol. 2019 May 15;93(11):e02312-18.
Author Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y.